U.S. National Cancer Institute Working Formulation of Non-Hodgkin's Lymphomas for Clinical Use

Robb‐Smith, A. H. T.

doi:10.1016/s0140-6736(82)90454-8

Cited by 20 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GOELAMS 064 multicenter trial enrolled patients aged 18 to 60 years with previously untreated, histologically proven FL, classified according to the Working-Formulation criteria of the National Cancer Institute (B, C, or D lymphoma) 19 and reviewed according to the Revised European-American Lymphoma (REAL) classification of the International Lymphoma Study Group (grades 1-3 center FL). 20 Patients with grade 3B FL were included, whereas those displaying transformed lymphoma were excluded.…”

Section: Patientsmentioning

confidence: 99%

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

Gyan

Foussard

Bertrand

et al. 2009

Blood

142

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT. Conditioning was performed with total body irradiation (TBI) and cyclophosphamide. The 9-year overall survival (OS) was similar in the HDT and conventional chemotherapy groups (76% and 80%, respectively). The 9-year progression-free survival (PFS) was higher in the ASCT than the chemotherapy group (64% vs 39%; P ‫؍‬ .004). A PFS plateau was observed in the HDT group after 7 years. On multivariate analysis, OS and PFS were independently affected by the performance status score, the number of nodal areas involved, and the treatment group. Secondary malignancies were more frequent in the HDT than in the chemotherapy group (6 secondary myelodysplastic syndrome/acute myeloid leukemia and 6 second solid tumor cancers vs IntroductionFollicular lymphomas (FLs) are a subgroup of B-cell nonHodgkin lymphomas (NHLs) accounting for 15% to 30% of newly diagnosed lymphomas. [1][2][3] The natural history of this disease is characterized by a long survival that contrasts with systematic relapses. Many chemotherapy regimens have been used for treatment but have not improved long-term outcome, which depends on initial prognostic factors such as the Follicular Lymphoma International Prognostic Index (FLIPI), 4 response to first-line therapy, and minimal residual disease indicated by positivity of the bcl2 rearrangement on analysis of the polymerase chain reaction (PCR). Although new therapeutic approaches, including purine analogs and anti-CD20 monoclonal antibodies, have shown impressive response rates and prolonged progression-free survival (PFS), their effects on overall survival (OS) have yet to be confirmed. The major improvement in the management of FLs has been achieved by the use of the anti-CD20 monoclonal antibody rituximab, which improved OS in combination with chemotherapy in all 4 prospective, randomized studies published to date. [5][6][7][8][9] Before the era of monoclonal antibodies, autologous stem cell transplantation (ASCT) was evaluated as an alternative approach to standard chemotherapy. Numerous studies have shown encouraging results for patients with relapsed follicular NHL, [10][11][12][13] 10,15,16 The fourth study, from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO), compared chemotherapy to ASCT with rituximab in both arms. 17 In 2005 we published the results of the Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS) 064 trial, showing a higher overall response rate and longer median event-free survival (EFS) in the high-dose therapy (HDT) group then the conventional chemotherapy group after a median follow-up of 5 years, with no difference in OS but a higher rate of secondary malignancies in the HDT group. 18 We report here the final results of this trial, after an extended follow-up period of 108 months (9 years...

show abstract

Section: Patientsmentioning

confidence: 99%

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

Gyan

Foussard

Bertrand

et al. 2009

Blood

142

View full text Add to dashboard Cite

show abstract

“…This multicenter trial enrolled patients 18 to 60 years old with previously untreated histologically proven follicular lymphoma, classified according to the Working-Formulation criteria of the National Cancer Institute (B, C, or D lymphoma) 27 and reviewed according to the Revised European-American Lymphoma classification (REAL) of the International Lymphoma Study Group (grades 1 to 3 center follicle lymphoma). 28 Patients with transformed lymphoma were excluded.…”

Section: Patientsmentioning

confidence: 99%

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

Deconinck

Foussard²,

Milpied³

et al. 2005

Blood

171

View full text Add to dashboard Cite

Doxorubicin-based immunochemotherapy, with interferon, has been shown to improve survival in patients with advanced follicular lymphoma. High-dose chemotherapy with stem-cell support is effective in follicular lymphoma in relapse but remains controversial as a first-line therapy. In a randomized study using a purged autologous stem-cell support, we compared these 2 approaches in patients with advanced follicular lymphoma. Newly diagnosed advanced follicular lymphoma patients (172 patients) were randomly assigned either to an immunochemotherapy regimen (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon) or to a high-dose therapy followed by purged autologous stem-cell transplantation. Compared with the patients who received chemotherapy and interferon, patients treated with high-dose therapy had a higher response rate (69% vs 81%, P ‫؍‬ .045) and a longer median event-free survival (not reached vs 45 months). This did not translate into a better survival rate due to an excess of secondary malignancies after transplantation. The Follicular Lymphoma Prognostic Index identified a subgroup of patients with a significantly higher event-free survival rate after highdose therapy. Autologous stem-cell transplantation cannot be considered as the standard first-line treatment of follicular lymphoma for patients younger than 60 years old with a high tumor burden. (Blood. 2005;105:3817-3823)

show abstract

“…The differential diagnosis of lymphoid malignancies has long been a difficult task and a source of debates for pathologists and clinicians. [1][2][3][4] To standardize knowledge into a widely accepted guideline, the WHO published a consensus lymphoma classification in 2001, 5 which was revised in 2008. 6 Even with the full spectrum of clinical and genetic features used in this guideline, uncertainty persists in pathologists' daily practice.…”

Section: Introductionmentioning

confidence: 99%

Automatic lymphoma classification with sentence subgraph mining from pathology reports

Luo

Sohani

Hochberg

et al. 2014

Journal of the American Medical Informatics Association

View full text Add to dashboard Cite

We compare our system with three baseline classifiers using standard n-grams, full MetaMap concepts, and filtered MetaMap concepts. Our system achieves high F-measures on multiple binary classifications of lymphoma (Burkitt lymphoma, 0.8; diffuse large B-cell lymphoma, 0.909; follicular lymphoma, 0.84; Hodgkin lymphoma, 0.912). Significance tests show that our system outperforms all three baselines. Moreover, feature analysis identifies subgraph features that contribute to improved performance; these features agree with the state-of-the-art knowledge about lymphoma classification. We also highlight how these unsupervised relation features may provide meaningful insights into lymphoma classification.

show abstract

U.S. National Cancer Institute Working Formulation of Non-Hodgkin's Lymphomas for Clinical Use

Cited by 20 publications

References 18 publications

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

Automatic lymphoma classification with sentence subgraph mining from pathology reports

Contact Info

Product

Resources

About